Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outp

Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-i

HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.24 per share in line with the Zacks

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst c

Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a l

-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/

-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/

Amova Asset Management Americas Inc. lessened its position in Prime Medicine, Inc. (NASDAQ: PRME) by

Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing cont

Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dis

Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its A

U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-

-- Arbitration tribunal declared that PM647 is within Prime Medicine’s "Field", confirming P

-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Med

Dow Jones gains 350 points, Iridium acquired by Rocket Lab for $8B, big stocks recording gains: Quid

Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgrad

HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to B

-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published

-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of

-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577

Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead

Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: P

MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Com

Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026

Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript

CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechno

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnol

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.28 per share versus the Zacks Conse

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst

CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnol

CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechn

Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Ou

LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and an

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of d

Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and low

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and low

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and low

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of d